Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin

J. J. Fiore, D. P. Kelsen, R. J. Gralla, E. S. Casper, G. Magill, E. Cheng, M. Ochoa

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Adenocarcinoma of unknown primary origin (ACUP) is a common oncologic problem for which there is no standard therapy. Forty-two patients with metastatic tumor were identified as having ACUP after extensive evaluation failed to reveal a primary site of disease. They were treated with an investigational chemotherapy regimen consisting of vindesine and doxorubicin. Of the 38 evaluable patients, six (16%) had major responses to chemotherapy. The median duration of response was 4 months. The median survival of the responding patients has not been reached, but is >8 months. The median survival of the nonresponding patients was 6 months. Vindesine and doxorubin were well tolerated. The major toxicity was leukopenia, with a median wbc count nadir of 2600/mm3. We conclude that the combination of vindesine and doxorubicin has some activity in ACUP, but does not improve the response rate seen with other regimens.

Original languageEnglish (US)
Pages (from-to)591-594
Number of pages4
JournalCancer Treatment Reports
Volume69
Issue number6
StatePublished - Sep 25 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Adenocarcinoma of unknown primary origin: Treatment with vindesine and doxorubicin'. Together they form a unique fingerprint.

Cite this